Skip to main content
SpringerLink
Log in

Suppressors of cytokine signaling (SOCS) and type 2 diabetes

  • Published:
Molecular Biology Reports Aims and scope Submit manuscript

Abstract

The suppressors of cytokine signaling (SOCS) proteins are originally identified as negative regulators of cytokine-activated Janus kinase/signal transducers and activators of transcription signaling pathway, but increasing evidence reveals that SOCS proteins play an important role in the development of type 2 diabetes involving regulation of the insulin signaling and pancreatic β-cell function, and that SOCS are promising to be the targets for the treatment of type 2 diabetes. In this review, we focus on the emerging role for SOCS and the potential drugs targeting SOCS for type 2 diabetes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, Shan Z, Liu J, Tian H, Ji Q, Zhu D, Ge J, Lin L, Chen L, Guo X, Zhao Z, Li Q, Zhou Z, Shan G, He J, China National Diabetes and Metabolic Disorders Study Group (2010) Prevalence of diabetes among men and women in China. N Engl J Med 362:1090–1101

    Google Scholar 

  2. Davis TM, Peters KE, Bruce DG, Davis WA (2012) Prevalence, incidence and prognosis of hepatobiliary disease in community-based patients with type 2 diabetes: the fremantle diabetes study. J Clin Endocrinol Metab 97:1581–1588

    PubMed  CAS  Google Scholar 

  3. Mauvais-Jarvis F, Sobngwi E, Porcher R, Riveline JP, Kevorkian JP, Vaisse C, Charpentier G, Guillausseau PJ, Vexiau P, Gautier JF (2004) Ketosis-prone type 2 diabetes in patients of sub-Saharan African origin: clinical pathophysiology and natural history of beta-cell dysfunction and insulin resistance. Diabetes 53:645–653

    PubMed  CAS  Google Scholar 

  4. Osei K, Gaillard T, Schuster DP (1997) Pathogenetic mechanisms of impaired glucose tolerance and type II diabetes in African-Americans. The significance of insulin secretion, insulin sensitivity, and glucose effectiveness. Diabetes Care 20:396–404

    PubMed  CAS  Google Scholar 

  5. Burgering BM, Coffer PJ (1995) Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature 376:599–602

    PubMed  CAS  Google Scholar 

  6. Taniguchi CM, Emanuelli B, Kahn CR (2006) Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol 7:85–96

    PubMed  CAS  Google Scholar 

  7. Halperin F, Lopez X, Manning R, Kahn CR, Kulkarni RN, Goldfine AB (2012) Insulin augmentation of glucose-stimulated insulin secretion is impaired in insulin-resistant humans. Diabetes 61:301–309

    PubMed Central  PubMed  CAS  Google Scholar 

  8. Endo TA, Masuhara M, Yokouchi M, Suzuki R, Sakamoto H, Mitsui K, Matsumoto A, Tanimura S, Ohtsubo M, Misawa H, Miyazaki T, Leonor N, Taniguchi T, Fujita T, Kanakura Y, Komiya S, Yoshimura A (1997) A new protein containing an SH2 domain that inhibits JAK kinases. Nature 387:921–924

    PubMed  CAS  Google Scholar 

  9. Magrangeas F, Boisteau O, Denis S, Jacques Y, Minvielle S (2001) Negative cross-talk between interleukin-3 and interleukin-11 is mediated by suppressor of cytokine signalling-3 (SOCS-3). Biochem J 353:223–230

    PubMed Central  PubMed  CAS  Google Scholar 

  10. Bahrenberg G, Behrmann I, Barthel A, Hekerman P, Heinrich PC, Joost HG, Becker W (2002) Identification of the critical sequence elements in the cytoplasmic domain of leptin receptor isoforms required for Janus kinase/signal transducer and activator of transcription activation by receptor heterodimers. Mol Endocrinol 16:859–872

    PubMed  CAS  Google Scholar 

  11. Shouda T, Hiraoka K, Komiya S, Hamada T, Zenmyo M, Iwasaki H, Isayama T, Fukushima N, Nagata K, Yoshimura A (2006) Suppression of IL-6 production and proliferation by blocking STAT3 activation in malignant soft tissue tumor cells. Cancer Lett 231:176–184

    PubMed  CAS  Google Scholar 

  12. Yu JH, Kim KH, Kim H (2008) SOCS 3 and PPAR-gamma ligands inhibit the expression of IL-6 and TGF-beta1 by regulating JAK2/STAT3 signaling in pancreas. Int J Biochem Cell Biol 40:677–688

    PubMed  CAS  Google Scholar 

  13. Minogue AM, Barrett JP, Lynch MA (2012) LPS-induced release of IL-6 from glia modulates production of IL-1 β in a JAK2-dependent manner. J Neuroinflammation 9:126

    PubMed Central  PubMed  CAS  Google Scholar 

  14. Pirvulescu M, Manduteanu I, Gan AM, Stan D, Simion V, Butoi E, Calin M, Simionescu M (2012) A novel pro-inflammatory mechanism of action of resistin in human endothelial cells: up-regulation of SOCS3 expression through STAT3 activation. Biochem Biophys Res Commun 422:321–326

    PubMed  CAS  Google Scholar 

  15. Yang Z, Hulver M, McMillan RP, Cai L, Kershaw EE, Yu L, Xue B, Shi H (2012) Regulation of insulin and leptin signaling by muscle suppressor of cytokine signaling 3 (SOCS3). PLoS ONE 7:e47493

    PubMed Central  PubMed  CAS  Google Scholar 

  16. Wada T, Hoshino M, Kimura Y, Ojima M, Nakano T, Koya D, Tsuneki H, Sasaoka T (2011) Both type I and II IFN induce insulin resistance by inducing different isoforms of SOCS expression in 3T3-L1 adipocytes. Am J Physiol Endocrinol Metab 300:E1112–E1123

    PubMed  CAS  Google Scholar 

  17. Lebrun P, Cognard E, Gontard P, Bellon-Paul R, Filloux C, Berthault MF, Magnan C, Ruberte J, Luppo M, Pujol A, Pachera N, Herchuelz A, Bosch F, Van Obberghen E (2010) The suppressor of cytokine signalling 2 (SOCS2) is a key repressor of insulin secretion. Diabetologia 53:1935–1946

    PubMed  CAS  Google Scholar 

  18. Collino M, Aragno M, Castiglia S, Miglio G, Tomasinelli C, Boccuzzi G, Thiemermann C, Fantozzi R (2010) Pioglitazone improves lipid and insulin levels in overweight rats on a high cholesterol and fructose diet by decreasing hepatic inflammation. Br J Pharmacol 160:1892–1902

    PubMed Central  PubMed  CAS  Google Scholar 

  19. Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ, Gonda TJ, Alexander WS, Metcalf D, Nicola NA, Hilton DJ (1997) A family of cytokine-inducible inhibitors of signalling. Nature 387:917–921

    PubMed  CAS  Google Scholar 

  20. Hilton DJ, Richardson RT, Alexander WS, Viney EM, Willson TA, Sprigg NS, Starr R, Nicholson SE, Metcalf D, Nicola NA (1998) Twenty proteins containing a C-terminal SOCS box form five structural classes. Proc Natl Acad Sci USA 95:114–119

    PubMed Central  PubMed  CAS  Google Scholar 

  21. Babon JJ, Laktyushin A, Kershaw NJ (2013) In vitro ubiquitination of cytokine signaling components. Methods Mol Biol 967:261–271

    PubMed  CAS  Google Scholar 

  22. Linossi EM, Nicholson SE (2012) The SOCS box-adapting proteins for ubiquitination and proteasomal degradation. IUBMB Life 64:316–323

    PubMed  CAS  Google Scholar 

  23. Waiboci LW, Ahmed CM, Mujtaba MG, Flowers LO, Martin JP, Haider MI, Johnson HM (2007) Both the suppressor of cytokine signaling 1 (SOCS-1) kinase inhibitory region and SOCS-1 mimetic bind to JAK2 autophosphorylation site: implications for the development of a SOCS-1 antagonist. J Immunol 178:5058–5068

    PubMed  CAS  Google Scholar 

  24. Sasaki A, Yasikawa H, Suzuk A, Kamizono S, Syoda T, Kinjyo I (1999) Cytokine-inducible SH2 protein-3 (CIS3/SOCS3) inhibits Janus tyrosine kinase by binding through the N-terminal kinase inhibitory region as well as SH2 domain. Genes Cells 4:339–351

    PubMed  CAS  Google Scholar 

  25. Venieratos PD, Drossopoulou GI, Kapodistria KD, Tsilibary EC, Kitsiou PV (2010) High glucose induces suppression of insulin signalling and apoptosis via upregulation of endogenous IL-1beta and suppressor of cytokine signalling-1 in mouse pancreatic beta cells. Cell Signal 22:791–800

    PubMed  CAS  Google Scholar 

  26. Gilardini L, Zulian A, Girola A, Redaelli G, Conti A, Invitti C (2010) Predictors of the early impairment of renal disease in human obesity. Int J Obes (Lond) 34:287–294

    CAS  Google Scholar 

  27. Feng ZP, Chandrashekaran IR, Low A, Speed TP, Nicholson SE, Norton RS (2012) The N-terminal domains of SOCS proteins: a conserved region in the disordered N-termini of SOCS4 and 5. Protein 80:946–957

    CAS  Google Scholar 

  28. Balasubramanyam M, Aravind S, Gokulakrishnan K, Prabu P, Sathishkumar C, Ranjani H, Mohan V (2011) Impaired miR-146a expression links subclinical inflammation and insulin resistance in Type 2 diabetes. Mol Cell Biochem 351:197–205

    PubMed  CAS  Google Scholar 

  29. Ghanim H, Abuaysheh S, Sia CL, Korzeniewski K, Chaudhuri A, Fernandez-Real JM, Dandona P (2009) Increase in plasma endotoxin concentrations and the expression of Toll-like receptors and suppressor of cytokine signaling-3 in mononuclear cells after a high-fat, high-carbohydrate meal: implications for insulin resistance. Diabetes Care 32:2281–2287

    PubMed Central  PubMed  CAS  Google Scholar 

  30. Broholm C, Brandt C, Schultz NS, Nielsen AR, Pedersen BK, Scheele C (2012) Deficient leukemia inhibitory factor signaling in muscle precursor cells from patients with type 2 diabetes. Am J Physiol Endocrinol Metab 303:E283–E292

    PubMed  CAS  Google Scholar 

  31. Karlsson EA, Sheridan PA, Beck MA (2010) Diet-induced obesity in mice reduces the maintenance of influenza-specific CD8+ memory T cells. J Nutr 140:1691–1697

    PubMed Central  PubMed  CAS  Google Scholar 

  32. Lebrun P, Cognard E, Bellon-Paul R, Gontard P, Filloux C, Jehl-Pietri C, Grimaldi P, Samson M, Pénicaud L, Ruberte J, Ferre T, Pujol A, Bosch F, Van Obberghen E (2009) Constitutive expression of suppressor of cytokine signalling-3 in skeletal muscle leads to reduced mobility and overweight in mice. Diabetologia 52:2201–2212

    PubMed  CAS  Google Scholar 

  33. Gylvin T, Nolsøe R, Hansen T, Nielsen EM, Bergholdt R, Karlsen AE, Billestrup N, Borch-Johnsen K, Pedersen O, Mandrup-Poulsen T, Nerup J, Pociot F (2004) Mutation analysis of suppressor of cytokine signalling 3, a candidate gene in type 1 diabetes and insulin sensitivity. Diabetologia 47:1273–1277

    PubMed  CAS  Google Scholar 

  34. Ueki K, Kondo T, Tseng YH, Kahn CR (2004) Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. Proc Natl Acad Sci USA 101:10422–10427

    PubMed Central  PubMed  CAS  Google Scholar 

  35. Jorgensen SB, O’Neill HM, Sylow L, Honeyman J, Hewitt KA, Palanivel R, Fullerton MD, Oberg L, Balendran A, Galic S, van der Poel C, Trounce IA, Lynch GS, Schertzer JD, Steinberg GR (2013) Deletion of skeletal muscle SOCS3 prevents insulin resistance in obesity. Diabetes 62:56–64

    PubMed Central  PubMed  CAS  Google Scholar 

  36. Palanivel R, Fullerton MD, Galic S, Honeyman J, Hewitt KA, Jorgensen SB, Steinberg GR (2012) Reduced Socs3 expression in adipose tissue protects female mice against obesity-induced insulin resistance. Diabetologia 55:3083–3093

    PubMed  CAS  Google Scholar 

  37. Ueki K, Kondo T, Kahn CR (2004) Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol Cell Biol 24:5434–5446

    PubMed Central  PubMed  CAS  Google Scholar 

  38. Sadowski CL, Choi TS, Le M, Wheeler TT, Wang LH, Sadowski HB (2001) Insulin induction of SOCS-2 and SOCS-3 mRNA expression in C2C12 skeletal muscle cells is mediated by Stat5. J Biol Chem 276:20703–20710

    PubMed  CAS  Google Scholar 

  39. Yang SJ, Xu CQ, Wu JW, Yang GS (2010) SOCS3 inhibits insulin signaling in porcine primary adipocytes. Mol Cell Biochem 345:45–52

    PubMed  CAS  Google Scholar 

  40. Emanuelli B, Peraldi P, Filloux C, Sawka-Verhelle D, Hilton D, Van Obberghen E (2000) SOCS-3 is an insulin-induced negative regulator of insulin signaling. J Biol Chem 275:15985–15991

    PubMed  CAS  Google Scholar 

  41. Emanuelli B, Peraldi P, Filloux C, Chavey C, Freidinger K, Hilton DJ, Hotamisligil GS, Van OE (2001) SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factor-alpha in the adipose tissue of obese mice. J Biol Chem 276:47944–47949

    PubMed  CAS  Google Scholar 

  42. Senn JJ, Klover PJ, Nowak IA, Zimmers TA, Koniaris LG, Furlanetto RW, Mooney RA (2003) Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem 278:13740–13746

    PubMed  CAS  Google Scholar 

  43. Dou L, Zhao T, Wang L, Huang X, Jiao J, Gao D, Zhang H, Shen T, Man Y, Wang S, Li J (2013) miR-200s contribute to interleukin-6 (IL-6)-induced insulin resistance in hepatocytes. J Biol Chem 288:22596–22606

    PubMed  CAS  Google Scholar 

  44. Ko WC, Liu TP, Cheng JT, Tzeng TF, Liu IM (2006) Effect of opioid μ-receptors activation on insulin signals damaged by tumor necrosis factor α in myoblast C2C12 cells. Neurosci Lett 397:274–278

    PubMed  CAS  Google Scholar 

  45. Waller AP, Huettner L, Kohler K, Lacombe VA (2012) Novel link between inflammation and impaired glucose transport during equine insulin resistance. Vet Immunol Immunopathol 149:208–215

    PubMed  CAS  Google Scholar 

  46. Weigert C, Hennige AM, Lehmann R, Brodbeck K, Baumgartner F, Schaüble M, Häring HU, Schleicher ED (2006) Direct cross-talk of interleukin-6 and insulin signal transduction via insulin receptor substrate-1 in skeletal muscle cells. J Biol Chem 281:7060–7067

    PubMed  CAS  Google Scholar 

  47. Shoelson SE, Lee J, Yuan M (2003) Inflammation and the IKK beta/I kappa B/NF-kappa B axis in obesity- and diet-induced insulin resistance. Int J Obes Relat Metab Disord 27:S49–S52

    PubMed  CAS  Google Scholar 

  48. Zolotnik IA, Figueroa TY, Yaspelkis BB III (2012) Insulin receptor and IRS-1 con-immunoprecipitation with SOCS-3, and IKKα/β phosphorylation are increased in obese Zucker rat skeletal muscle. Life Sci 91:816–822

    PubMed Central  PubMed  CAS  Google Scholar 

  49. Chaves de Souza JA, Nogueira AV, Chaves de Souza PP, Kim YJ, Silva Lobo C, Pimentel Lopes de Oliveira GJ, Cirelli JA, Garlet GP, Rossa C Jr (2013) SOCS3 expression correlates with severity of inflammation, expression of proinflammatory cytokines, and activation of STAT3 and p38 MAPK in LPS-induced inflammation in vivo. Mediators Inflamm 2013:650812

    PubMed Central  PubMed  Google Scholar 

  50. Pinto Lde F, Compri CM, Fornari JV, Bartchewsky W, Cintra DE, Trevisan M, Carvalho Pde O, Ribeiro ML, Velloso LA, Saad MJ, Pedrazzoli J Jr, Gambero A (2010) The immunosuppressant drug, thalidomide, improves hepatic alterations induced by a high-fat diet in mice. Liver Int 30:603–610

    PubMed  Google Scholar 

  51. Eguchi M, Gillis LC, Liu Y, Lyakhovsky N, Du M, McDermott JC, Sweeney G (2007) Regulation of SOCS-3 expression by leptin and its co-localization with insulin receptor in rat skeletal muscle cells. Mol Cell Endocrinol 267:38–45

    PubMed  CAS  Google Scholar 

  52. Passos MC, Toste FP, Dutra SC, Trotta PA, Toste FP, Lisboa PC, de Moura EG (2009) Role of neonatal hyperleptinaemia on serum adiponectin and suppressor of cytokine signaling-3 expression in young rats. Br J Nutr 101:205–256

    Google Scholar 

  53. Muse ED, Lam TK, Scherer PE, Rossetti L (2007) Hypothalamic resistin induces hepatic insulin resistance. J Clin Invest 117:1670–1678

    PubMed Central  PubMed  CAS  Google Scholar 

  54. Steppan CM, Wang J, Whiteman EL, Birnbaum MJ, Lazar MA (2005) Activation of SOCS-3 by resistin. Mol Cell Biol 25:1569–1575

    PubMed Central  PubMed  CAS  Google Scholar 

  55. Krusenstjerna-Hafstrøm T, Clasen BF, Møller N, Jessen N, Pedersen SB, Christiansen JS, Jørgensen JO (2011) Growth hormone (GH)-induced insulin resistance is rapidly reversible: an experimental study in GH-deficient adults. J Clin Endocrinol Metab 96:2548–2557

    PubMed  Google Scholar 

  56. Zheng RD, Liao LH, Ye J, Wang CB, Gao JZ, Ying YQ, Ning Q, Luo XP (2013) Effects of SOCS1/3 gene silencing on the expression of C/EBPα and PPARγ during differentiation and maturation of rat preadipocytes. Pediatr Res 73:263–267

    PubMed  CAS  Google Scholar 

  57. Fasshauer M, Kralisch S, Klier M, Lossner U, Bluher M, Klein J, Paschke R (2004) Insulin resistance-inducing cytokines differentially regulate SOCS mRNA expression via growth factor- and Jak/Stat-signaling pathways in 3T3-L1 adipocytes. J Endocrinol 181:129–138

    PubMed  CAS  Google Scholar 

  58. Dominici FP, Argentino DP, Muñoz MC, Miquet JG, Sotelo AI, Turyn D (2005) Influence of the crosstalk between growth hormone and insulin signalling on the modulation of insulin sensitivity. Growth Horm IGF Res 15:324–336

    PubMed  CAS  Google Scholar 

  59. Dominici FP, Steinhardt AP, Rodriguez G, Taverna MJ, Poskus E, Frechtel G (2013) Common variants in SOCS7 gene predict obesity, disturbances in lipid metabolism and insulin resistance. Nutr Metab Cardiovasc Dis 23:424–431

    Google Scholar 

  60. Banks AS, Li J, McKeag L, Hribal ML, Kashiwada M, Accili D, Rothman PB (2005) Deletion of SOCS7 leads to enhanced insulin action and enlarged islets of Langerhans. J Clin Invest 115:2462–2471

    PubMed Central  PubMed  CAS  Google Scholar 

  61. Mooney RA, Senn J, Cameron S, Inamdar N, Boivin LM, Shang Y, Furlanetto RW (2001) Suppressors of cytokine signaling-1 and -6 associate with and inhibit the insulin receptor. A potential mechanism for cytokine-mediated insulin resistance. J Biol Chem 276:25889–25893

    PubMed  CAS  Google Scholar 

  62. Krebs DL, Uren RT, Metcalf D, Rakar S, Zhang JG, Starr R, De Souza DP, Hanzinikolas K, Eyles J, Connolly LM, Simpson RJ, Nicola NA, Nicholson SE, Baca M, Hilton DJ, Alexander WS (2002) SOCS-6 binds to insulin receptor substrate 4, and mice lacking the SOCS-6 gene exhibit mild growth retardation. Mol Cell Biol 22:4567–4578

    PubMed Central  PubMed  CAS  Google Scholar 

  63. Rui L, Yuan M, Frantz D, Shoelson S, White MF (2002) SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J Biol Chem 277:42394–42398

    PubMed  CAS  Google Scholar 

  64. Lu XM, Tompkins R, Fischman A (2013) Burn injury-induced IRS-1 degradation in mouse. Int J Burns Trauma 3:37–48

    PubMed Central  PubMed  CAS  Google Scholar 

  65. Wang Y, Nishina PM, Naggert JK (2009) Degradation of IRS1 leads to impaired glucose uptake in adipose tissue of the type 2 diabetes mouse model TALLYHO/Jng. J Endocrinol 203:65–74

    PubMed Central  PubMed  CAS  Google Scholar 

  66. Tyers M, Willems AR (1999) One ring to rule a superfamily of E3 ubiquitin ligases. Science 284(601):603–604

    Google Scholar 

  67. Kamizono S, Hanada T, Yasukawa H, Minoguchi S, Kato R, Minoguchi M, Hattori K, Hatakeyama S, Yada M, Morita S, Kitamura T, Kato H, Ki Nakayama, Yoshimura A (2001) The SOCS box of SOCS-1 accelerates ubiquitin-dependent proteolysis of TE-JAK2. J Biol Chem 276:12530–12538

    PubMed  CAS  Google Scholar 

  68. Kawaguchi T, Yoshida T, Harada M, Hisamoto T, Nagao Y, Ide T, Taniguchi E, Kumemura H, Hanada S, Maeyama M, Baba S, Koga H, Kumashiro R, Ueno T, Ogata H, Yoshimura A, Sata M (2004) Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 165:1499–1508

    PubMed Central  PubMed  CAS  Google Scholar 

  69. Del Guerra S, Bugliani M, D’Aleo V, Del Prato S, Boggi U, Mosca F, Filipponi F, Lupi R (2010) G-protein-coupled receptor 40 (GPR40) expression and its regulation in human pancreatic islets: the role of type 2 diabetes and fatty acids. Nutr Metab Cardiovasc Dis 20:22–25

    PubMed  Google Scholar 

  70. Santangelo C, Scipioni A, Marselli L, Marchetti P, Dotta F (2005) Suppressor of cytokine signaling gene expression in human pancreatic islets: modulation by cytokines. Eur J Endocrinol 152:485–489

    PubMed  CAS  Google Scholar 

  71. Puff R, Dames P, Weise M, Göke B, Parhofer K, Lechner A (2010) No non-redundant function of suppressor of cytokine signaling 2 in insulin producing β-cells. Islets 2:252–257

    PubMed Central  PubMed  Google Scholar 

  72. Lindberg K, Rønn SG, Tornehave D, Richter H, Hansen JA, Rømer J, Jackerott M, Billestrup N (2005) Regulation of pancreatic beta-cell mass and proliferation by SOCS-3. J Mol Endocrinol 35:231–243

    PubMed  CAS  Google Scholar 

  73. Laubner K, Kieffer TJ, Lam NT, Niu X, Jakob F, Seufert J (2005) Inhibition of preproinsulin gene expression by leptin induction of suppressor of cytokine signaling 3 in pancreatic beta-cells. Diabetes 54:3410–3417

    PubMed  CAS  Google Scholar 

  74. Nakata M, Okada T, Ozawa K, Yada T (2007) Resistin induces insulin resistance in pancreatic islets to impair glucose-induced insulin release. Biochem Biophys Res Commun 353:1046–1051

    PubMed  CAS  Google Scholar 

  75. Baker MS, Chen X, Rotramel A, Nelson J, Kaufman DB (2003) Proinflammatory cytokines induce NF-kappaB-dependent/NO-independent chemokine gene expression in MIN6 beta cells. J Surg Res 110:295–303

    PubMed  CAS  Google Scholar 

  76. Moore F, Naamane N, Colli ML, Bouckenooghe T, Ortis F, Gurzov EN, Igoillo-Esteve M, Mathieu C, Bontempi G, Thykjaer T, Ørntoft TF, Eizirik DL (2011) STAT1 is a master regulator of pancreatic {beta}-cell apoptosis and islet inflammation. J Biol Chem 286:929–941

    PubMed Central  PubMed  CAS  Google Scholar 

  77. Ortis F, Naamane N, Flamez D, Ladrière L, Moore F, Cunha DA, Colli ML, Thykjaer T, Thorsen K, Orntoft TF, Eizirik DL (2010) Cytokines interleukin-1beta and tumor necrosis factor-alpha regulate different transcriptional and alternative splicing networks in primary beta-cells. Diabetes 59:358–374

    PubMed Central  PubMed  CAS  Google Scholar 

  78. Cottet S, Dupraz P, Hamburger F, Dolci W, Jaquet M, Thorens B (2001) SOCS-1 protein prevents Janus Kinase/STAT-dependent inhibition of beta cell insulin gene transcription and secretion in response to interferon-gamma. J Biol Chem 276:25862–25870

    PubMed  CAS  Google Scholar 

  79. Bruun C, Heding PE, Rønn SG, Frobøse H, Rhodes CJ, Mandrup-Poulsen T, Billestrup N (2009) Suppressor of cytokine signalling-3 inhibits tumor necrosis factor-alpha induced apoptosis and signalling in beta cells. Mol Cell Endocrinol 311:32–38

    PubMed  CAS  Google Scholar 

  80. Rønn SG, Börjesson A, Bruun C, Heding PE, Frobøse H, Mandrup-Poulsen T, Karlsen AE, Rasschaert J, Sandler S, Billestrup N (2008) Suppressor of cytokine signalling-3 expression inhibits cytokine-mediated destruction of primary mouse and rat pancreatic islets and delays allograft rejection. Diabetologia 51:1873–1882

    PubMed  Google Scholar 

  81. Jacobsen ML, Rønn SG, Bruun C, Larsen CM, Eizirik DL, Mandrup-Poulsen T, Billestrup N (2009) IL-1beta-induced chemokine and Fas expression are inhibited by suppressor of cytokine signalling-3 in insulin-producing cells. Diabetologia 52:281–288

    PubMed  CAS  Google Scholar 

  82. Karlsen AE, Heding PE, Frobøse H, Rønn SG, Kruhøffer M, Orntoft TF, Darville M, Eizirik DL, Pociot F, Nerup J, Mandrup-Poulsen T, Billestrup N (2004) Suppressor of cytokine signalling (SOCS)-3 protects beta cells against IL-1beta-mediated toxicity through inhibition of multiple nuclear factor-kappaB-regulated proapoptotic pathways. Diabetologia 47:1998–2011

    PubMed  CAS  Google Scholar 

  83. Chong MM, Chen Y, Darwiche R, Dudek NL, Irawaty W, Santamaria P, Allison J, Kay TW, Thomas HE (2004) Suppressor of cytokine signaling-1 overexpression protects pancreatic beta cells from CD8+ T cell-mediated autoimmune destruction. J Immunol 172:5714–5721

    PubMed  CAS  Google Scholar 

  84. Sun Q, Xiang RL, Yang YL, Feng K, Zhang K, Ding WY (2013) Suppressor of cytokine signaling 1 protects rat pancreatic islets from cytokine-induced apoptosis through Janus kinase/signal transducers and activators of transcription pathway. Chin Med J (Engl) 126:4048–4053

    CAS  Google Scholar 

  85. Zaitseva II, Hultcrantz M, Sharoyko V, Flodström-Tullberg M, Zaitsev SV, Berggren PO (2009) Suppressor of cytokine signaling-1 inhibits caspase activation and protects from cytokine-induced beta cell death. Cell Mol Life Sci 66:3787–3795

    PubMed  CAS  Google Scholar 

  86. Suo GJ, Qin J, Zhong CP, Zhao ZX (2010) Suppressor of cytokine signaling 1 inhibits apoptosis of islet grafts through caspase 3 and apoptosis-inducing factor pathways in rats. Transpl Proc 42:2658–2661

    CAS  Google Scholar 

  87. Rezende LF, Vieira AS, Negro A, Langone F, Boschero AC (2009) Ciliary neurotrophic factor (CNTF) signals through STAT3-SOCS3 pathway and protects rat pancreatic islets from cytokine-induced apoptosis. Cytokine 46:65–71

    PubMed  CAS  Google Scholar 

  88. Standaert ML, Kanoh Y, Sajan MP, Bandyopadhyay G, Farese RV (2002) Cbl, IRS-1, and IRS-2 mediate effects of rosiglitazone on PI3K, PKC-lambda, and glucose transport in 3T3/L1 adipocytes. Endocrinology 143:1705–1716

    PubMed  CAS  Google Scholar 

  89. Kanatani Y, Usui I, Ishizuka K, Bukhari A, Fujisaka S, Urakaze M, Haruta T, Kishimoto T, Naka T, Kobayashi M (2007) Effects of pioglitazone on suppressor of cytokine signaling 3 expression: potential mechanisms for its effects on insulin sensitivity and adiponectin expression. Diabetes 56:795–803

    PubMed  CAS  Google Scholar 

  90. Aoyama T, Ikejima K, Kon K, Okumura K, Arai K, Watanabe S (2009) Pioglitazone promotes survival and prevents hepatic regeneration failure after partial hepatectomy in obese and diabetic KK-A(y) mice. Hepatology 49:1636–1644

    PubMed  CAS  Google Scholar 

  91. Lagathu C, Bastard JP, Auclair M, Maachi M, Capeau J, Caron M (2003) Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone. Biochem Biophys Res Commun 311:372–379

    PubMed  CAS  Google Scholar 

  92. Pazienza V, Clément S, Pugnale P, Conzelman S, Foti M, Mangia A, Negro F (2007) The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. Hepatology 45:1164–1171

    PubMed  CAS  Google Scholar 

  93. Pazienza V, Vinciguerra M, Andriulli A, Mangia A (2010) Hepatitis C virus core protein genotype 3a increases SOCS-7 expression through PPAR-{gamma} in Huh-7 cells. J Gen Virol 91:1678–1686

    PubMed  CAS  Google Scholar 

  94. Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:2457–2471

    PubMed  CAS  Google Scholar 

  95. Singh S, Loke YK, Furberg CD (2007) Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care 30:2148–2153

    PubMed  CAS  Google Scholar 

  96. Risérus U, Sprecher D, Johnson T, Olson E, Hirschberg S, Liu A, Fang Z, Hegde P, Richards D, Sarov-Blat L, Strum JC, Basu S, Cheeseman J, Fielding BA, Humphreys SM, Danoff T, Moore NR, Murgatroyd P, O’Rahilly S, Sutton P, Willson T, Hassall D, Frayn KN, Karpe F (2008) Activation of peroxisome proliferator-activated receptor (PPAR) delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. Diabetes 57:332–339

    PubMed  Google Scholar 

  97. Ye JM, Tid-Ang J, Turner N, Zeng XY, Li HY, Cooney GJ, Wulff EM, Sauerberg P, Kraegen EW (2011) PPARδ agonists have opposing effects on insulin resistance in high fat-fed rats and mice due to different metabolic responses in muscle. Br J Pharmacol 163:556–566

    PubMed Central  PubMed  CAS  Google Scholar 

  98. Rodríguez-Calvo R, Serrano L, Coll T, Moullan N, Sánchez RM, Merlos M, Palomer X, Laguna JC, Michalik L, Wahli W, Vázquez-Carrera M (2008) Activation of peroxisome proliferator-activated receptor beta/delta inhibits lipopolysaccharideinduced cytokine production in adipocytes by lowering nuclear factor-kappaB activity via extracellular signal-related kinase 1/2. Diabetes 57:2149–2157

    PubMed Central  PubMed  Google Scholar 

  99. Serrano-Marco L, Rodríguez-Calvo R, El Kochairi I, Palomer X, Michalik L, Wahli W, Vázquez-Carrera M (2011) Activation of peroxisome proliferator-activated receptor-β/-δ (PPAR-β/-δ) ameliorates insulin signaling and reduces SOCS3 levels by inhibiting STAT3 in interleukin-6-stimulated adipocytes. Diabetes 60:1990–1999

    PubMed Central  PubMed  CAS  Google Scholar 

  100. Serrano-Marco L, Barroso E, El Kochairi I, Palomer X, Michalik L, Wahli W, Vázquez-Carrera M (2012) The peroxisome proliferator-activated receptor (PPAR) β/δ agonist GW501516 inhibits IL-6-induced signal transducer and activator of transcription 3 (STAT3) activation and insulin resistance in human liver cells. Diabetologia 55:743–751

    PubMed  CAS  Google Scholar 

  101. McCall KD, Holliday D, Dickerson E, Wallace B, Schwartz AL, Schwartz C, Lewis CJ, Kohn LD, Schwartz FL (2010) Phenylmethimazole blocks palmitate-mediated induction of inflammatory cytokine pathways in 3T3L1 adipocytes and RAW 264.7 macrophages. J Endocrinol 207:343–353

    PubMed  CAS  Google Scholar 

  102. Gedulin BR, Nikoulina SE, Smith PA, Gedulin G, Nielsen LL, Baron AD, Parkes DG, Young AA (2005) Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight. Endocrinology 146:2069–2076

    PubMed  CAS  Google Scholar 

  103. Chen J, Couto FM, Minn AH, Shalev A (2006) Exenatide inhibits beta-cell apoptosis by decreasing thioredoxin-interacting protein. Biochem Biophys Res Commun 346:1067–1074

    PubMed  CAS  Google Scholar 

  104. Park YJ, Ao Z, Kieffer TJ, Chen H, Safikhan N, Thompson DM, Meloche M, Warnock GL, Marzban L (2012) The glucagon-like peptide-1 receptor agonist exenatide restores impaired pro-islet amyloid polypeptide processing in cultured human islets: implications in type 2 diabetes and islet transplantation. Diabetologia 56:508–519

    PubMed  Google Scholar 

  105. Luo J, Nguyen K, Chen M, Tran T, Hao J, Tian B, Rulifson IC, Zhang Y, Tian L, Zhang Y, Lopez E, Lin DC, Wang Y, Ma Z, Houze J, Guo Z (2013) Evaluating insulin secretagogues in a humanized mouse model with functional human islets. Metabolism 62:90–99

    PubMed  CAS  Google Scholar 

  106. Cechin SR, Pérez-Álvarez I, Fenjves E, Molano RD, Pileggi A, Berggren PO, Ricordi C, Pastori RL (2012) Anti-inflammatory properties of Exenatide in human pancreatic islets. Cell Transplant 21:633–648

    PubMed  CAS  Google Scholar 

  107. Chaudhuri A, Ghanim H, Vora M, Sia CL, Korzeniewski K, Dhindsa S, Makdissi A, Dandona P (2012) Exenatide exerts a potent antiinflammatory effect. J Clin Endocrinol Metab 97:198–207

    PubMed Central  PubMed  CAS  Google Scholar 

  108. Owens DR, Monnier L, Bolli GB (2013) Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus. Diabetes Metab 39:485–496

    PubMed  CAS  Google Scholar 

  109. Yuan GH, Song WL, Huang YY, Guo XH, Gao Y (2012) Efficacy and tolerability of exenatide monotherapy in obese patients with newly diagnosed type 2 diabetes: a randomized, 26 weeks metformin-controlled, parallel-group study. Chin Med J (Engl) 125:2677–2681

    CAS  Google Scholar 

  110. Alves C, Batel-Marques F, Macedo AF (2012) A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. Diabetes Res Clin Pract 98:271–284

    PubMed  CAS  Google Scholar 

  111. Lv N, Song MY, Kim EK, Park JW, Kwon KB, Park BH (2008) Guggulsterone, a plant sterol, inhibits NF-kappaB activation and protects pancreatic beta cells from cytokine toxicity. Mol Cell Endocrinol 289:49–59

    PubMed  CAS  Google Scholar 

  112. Lv N, Kim EK, Song MY, Choi HN, Moon WS, Park SJ, Park JW, Kwon KB, Park BH (2009) JANEX-1, a JAK3 inhibitor, protects pancreatic islets from cytokine toxicity through downregulation of NF-kappaB activation and the JAK/STAT pathway. Exp Cell Res 315:2064–2071

    PubMed  CAS  Google Scholar 

  113. Watanabe T, Yoshida M, Fujiwara K, Kageyama-Yahara N, Kuramoto H, Shimada Y, Kadowaki M (2010) The traditional herbal medicine saireito exerts its inhibitory effect on murine oxazolone-induced colitis via the induction of Th1-polarized immune responses in the mucosal immune system of the colon. Int Arch Allergy Immunol 151:98–106

    PubMed  Google Scholar 

  114. Fang MF, Tan F, Zhang X (2010) Effects of Huatan Tongluo Granule on SOCS-3 and TNF-alpha expressions in patients with acute cerebral infarction. Zhongguo Zhong Xi Yi Jie He Za Zhi 30:1142–1145 In Chinese

    PubMed  Google Scholar 

  115. Gao J, Tang CL, Liu RJ, Chen XL, Xie H, Hou YX, Yu M, Liu ZL (2013) Effect of different intensities of electroacupuncture stimulation on expression of SOCS-3 and PPAR-gamma mRNA in adipose tissues of obesity rats. Zhen Ci Yan Jiu 38:31–34 In Chinese

    PubMed  CAS  Google Scholar 

  116. Yang P, Feng J (2013) Effect of Chailingtiaogan granule in treating rats with non-alcoholic fatty liver disease. Chin Integr Trad West med Dig 21:301–304 In Chinese

    Google Scholar 

  117. Liu R, Li JP, Wu JJ, Fan JJ, Mo XM (2012) Effects of Danqing soft capsule (DSC) on expression of SOCS-3 in rats’ liver with non-alcoholic fatty liver disease (NAFLD). Chin Arch Trad Chin Med 30:191–193 In Chinese

    Google Scholar 

  118. Feng XT, Wang TZ, Chen Y, Liu JB, Liu Y, Wang WJ (2012) Pollen Typhae total flavone improves insulin-induced glucose uptake through the β-arrestin-2-mediated signaling in C2C12 myotubes. Int J Mol Med 30:914–922

    PubMed  CAS  Google Scholar 

  119. Chao M, Zou D, Zhang Y, Chen Y, Wang M, Wu H, Ning G, Wang W (2009) Improving insulin resistance with traditional Chinese medicine in type 2 diabetic patients. Endocrine 36:268–274

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by the National Natural Science Foundation of China (No. 81202677, No. 81160455) and Guangxi Natural Science Foundation (No. 2012GXNSFBA053103). No potential conflict of interest relevant to this article was reported.

Author information

Authors and Affiliations

  1. Guangxi Scientific Experimental Center of Traditional Chinese Medicine, Guangxi University of Chinese Medicine, Nanning, 530001, People’s Republic of China

    Xiaotao Feng & Jing Leng

  2. Ruikang Hospital, Guangxi University of Chinese Medicine, Nanning, 530011, People’s Republic of China

    Hongzhen Tang

  3. The First Affiliated Hospital, Guangxi University of Chinese Medicine, 89-9 Dongge Road, Nanning, 530023, People’s Republic of China

    Qiuyan Jiang

Authors
  1. Xiaotao Feng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hongzhen Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jing Leng
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Qiuyan Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Qiuyan Jiang.

Additional information

Xiaotao Feng and Hongzhen Tang contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Feng, X., Tang, H., Leng, J. et al. Suppressors of cytokine signaling (SOCS) and type 2 diabetes. Mol Biol Rep 41, 2265–2274 (2014). https://doi.org/10.1007/s11033-014-3079-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11033-014-3079-8

Keywords

Search

Navigation